Canuevo Biotech

Canuevo is developing drug delivery mechanisms for cannabinoid formulations to increase delivery efficacy. The company's drug delivery platforms are specifically designed to achieve the highest efficacy for particular chronic syndroms and conditions. They try to address the lack of standardization and acceptance of cannabis derived medication within the medical and regulatory community. Illnesses and conditions targeted by Canuevo's platforms include IBS, basal skin carcinoma, epilepsy, support medication for treating opiate dependency and pain regulation. Canuevo was started by Nils Rehmann, PhD and Daniel Carbo, MEng.